Search research articles
Contact Us
Filters
Showing results (81-90 of 121) with videos related to
Page
of 13
Sort By:
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|
October 1, 2018
Non-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar Agent
Lars Erik Kristensen, Rieke Alten, Luis Puig, et al.
American Journal of Clinical Dermatology
|
March 31, 2018
Correction to: Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)
Andrew Blauvelt, Kim A Papp, Christopher E M Griffiths, et al.
American Journal of Clinical Dermatology
|
January 12, 2017
Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)
Andrew Blauvelt, Kim A Papp, Christopher E M Griffiths, et al.
Dermatology and Therapy
|
September 16, 2024
Complete Skin Clearance is Associated with the Greatest Benefits to Health-Related Quality of Life and Perceived Symptoms for Patients with Psoriasis
Matthias Augustin, Alice B Gottlieb, Mark Lebwohl, et al.
Rheumatology and Therapy
|
July 3, 2023
A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
Bruce W Kirkham, Alexander Egeberg, Frank Behrens, et al.
Journal of the American Academy of Dermatology
|
October 4, 2016
Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms: Results from 3 phase III psoriasis clinical trials
Alexandra B Kimball, Thomas Luger, Alice Gottlieb, et al.
Advances in Therapy
|
December 14, 2022
Comparative Effectiveness of Biologics Across Subgroups of Patients with Moderate-to-Severe Plaque Psoriasis: Results at Week 12 from the PSoHO Study in a Real-World Setting
Charles Lynde, Elisabeth Riedl, Julia-Tatjana Maul, et al.
Expert Opinion on Drug Safety
|
September 5, 2024
Treatment-emergent Candida infections in patients with psoriasis, psoriatic arthritis, and axial spondyloarthritis treated with ixekizumab: an integrated safety analysis of 25 clinical studies
Sergio Schwartzman, Luis Puig, Arnon D Cohen, et al.
Dermatology and Therapy
|
August 17, 2024
Progression of Quality of Life in Patients with Plaque Psoriasis Who Achieved Three or More Years of Complete Skin Clearance with Guselkumab Treatment: a Post hoc Analysis of the VOYAGE 1 Clinical Trial
Luis Puig, Antonio Costanzo, Elke M G J de Jong, et al.
American Journal of Clinical Dermatology
|
October 7, 2023
Guselkumab-Treated Patients with Plaque Psoriasis Who Achieved Complete Skin Clearance for ≥ 156 Consecutive Weeks: A Post-Hoc Analysis From the VOYAGE 1 Clinical Trial
Luis Puig, Antonio Costanzo, Elke M G J de Jong, et al.
Page
of 13
Search research articles
Search
Showing results (81-90 of 121) with videos related to
Sort By:
Page
of 13
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|
October 1, 2018
Non-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar Agent
Lars Erik Kristensen, Rieke Alten, Luis Puig, et al.
American Journal of Clinical Dermatology
|
March 31, 2018
Correction to: Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)
Andrew Blauvelt, Kim A Papp, Christopher E M Griffiths, et al.
American Journal of Clinical Dermatology
|
January 12, 2017
Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)
Andrew Blauvelt, Kim A Papp, Christopher E M Griffiths, et al.
Dermatology and Therapy
|
September 16, 2024
Complete Skin Clearance is Associated with the Greatest Benefits to Health-Related Quality of Life and Perceived Symptoms for Patients with Psoriasis
Matthias Augustin, Alice B Gottlieb, Mark Lebwohl, et al.
Rheumatology and Therapy
|
July 3, 2023
A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
Bruce W Kirkham, Alexander Egeberg, Frank Behrens, et al.
Journal of the American Academy of Dermatology
|
October 4, 2016
Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms: Results from 3 phase III psoriasis clinical trials
Alexandra B Kimball, Thomas Luger, Alice Gottlieb, et al.
Advances in Therapy
|
December 14, 2022
Comparative Effectiveness of Biologics Across Subgroups of Patients with Moderate-to-Severe Plaque Psoriasis: Results at Week 12 from the PSoHO Study in a Real-World Setting
Charles Lynde, Elisabeth Riedl, Julia-Tatjana Maul, et al.
Expert Opinion on Drug Safety
|
September 5, 2024
Treatment-emergent Candida infections in patients with psoriasis, psoriatic arthritis, and axial spondyloarthritis treated with ixekizumab: an integrated safety analysis of 25 clinical studies
Sergio Schwartzman, Luis Puig, Arnon D Cohen, et al.
Dermatology and Therapy
|
August 17, 2024
Progression of Quality of Life in Patients with Plaque Psoriasis Who Achieved Three or More Years of Complete Skin Clearance with Guselkumab Treatment: a Post hoc Analysis of the VOYAGE 1 Clinical Trial
Luis Puig, Antonio Costanzo, Elke M G J de Jong, et al.
American Journal of Clinical Dermatology
|
October 7, 2023
Guselkumab-Treated Patients with Plaque Psoriasis Who Achieved Complete Skin Clearance for ≥ 156 Consecutive Weeks: A Post-Hoc Analysis From the VOYAGE 1 Clinical Trial
Luis Puig, Antonio Costanzo, Elke M G J de Jong, et al.
Page
of 13